- Home
- PESI vs DSGN Comparison
PESI vs DSGN Comparison
Compare PESI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- DSGN
- Stock Information
- Founded
- PESI 1990
- DSGN 2017
- Country
- PESI United States
- DSGN United States
- Employees
- PESI N/A
- DSGN N/A
- Industry
- PESI Environmental Services
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- PESI Industrials
- DSGN Health Care
- Exchange
- PESI Nasdaq
- DSGN Nasdaq
- Market Cap
- PESI 205.4M
- DSGN 208.9M
- IPO Year
- PESI 1992
- DSGN 2021
- Fundamental
- Price
- PESI $12.16
- DSGN $5.82
- Analyst Decision
- PESI
- DSGN
- Analyst Count
- PESI 0
- DSGN 0
- Target Price
- PESI N/A
- DSGN N/A
- AVG Volume (30 Days)
- PESI 95.7K
- DSGN 184.3K
- Earning Date
- PESI 08-07-2025
- DSGN 11-06-2025
- Dividend Yield
- PESI N/A
- DSGN N/A
- EPS Growth
- PESI N/A
- DSGN N/A
- EPS
- PESI N/A
- DSGN N/A
- Revenue
- PESI $60,019,000.00
- DSGN N/A
- Revenue This Year
- PESI $8.35
- DSGN N/A
- Revenue Next Year
- PESI $82.81
- DSGN N/A
- P/E Ratio
- PESI N/A
- DSGN N/A
- Revenue Growth
- PESI N/A
- DSGN N/A
- 52 Week Low
- PESI $6.25
- DSGN $2.60
- 52 Week High
- PESI $16.25
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- PESI 58.13
- DSGN 59.68
- Support Level
- PESI $11.33
- DSGN $4.92
- Resistance Level
- PESI $12.21
- DSGN $6.57
- Average True Range (ATR)
- PESI 0.42
- DSGN 0.46
- MACD
- PESI 0.01
- DSGN 0.05
- Stochastic Oscillator
- PESI 75.00
- DSGN 60.48
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.